№ 127 · biology

How a gut hormone became a weight drug

A reader asked how a gut hormone became a weight drug. The short answer: after a meal, your gut releases a small hormone called GLP-1 that tells the pancreas to make insulin and tells the brain you have eaten. On its own it is gone from the blood within minutes. The drugs are GLP-1 rebuilt so that it lasts a day, then a week: one or two of its building blocks changed, and a way to hitch a ride on one of the most plentiful proteins in blood.

The hormone

In the early 1980s Joel Habener's lab copied the gene for glucagon, a pancreas hormone, out of the anglerfish. The gene held more than glucagon. Alongside it sat other stretches that looked like glucagon. Graeme Bell in Chicago found two such stretches in the mammal genes, and they were named glucagon-like peptides 1 and 2. Cells cut the long protein the gene makes into pieces, and which pieces they keep depends on the tissue. Cells in the gut keep GLP-1.

Which piece was the working hormone was not obvious. Svetlana Mojsov, a peptide chemist at the same hospital, guessed that the active form started at building block 7 of the predicted sequence, made it, and raised antibodies to find it in rat intestine. In 1987 she, Habener and Gordon Weir showed that this form, GLP-1(7-37), made a rat pancreas release insulin. Later work showed it does that only when blood sugar is raised. Jens Juul Holst's group in Copenhagen showed that a shortened piece taken from the gut released insulin too, and they and others went on to show that GLP-1 slows the stomach and cuts appetite and food intake. Habener, Mojsov and Lotte Bjerre Knudsen shared the 2024 Lasker clinical award for this line of work.

The problem: it lasts minutes

Injected into a vein, natural GLP-1 has a half-life of about a minute and a half; under the skin, about an hour and a half. Two things remove it. An enzyme in the blood, DPP-4, clips off its first two building blocks, and the front end is the part the receptor needs. And a molecule that small is filtered out by the kidneys. A drip in hospital could keep it up long enough to bring a diabetic patient's blood sugar down, but nobody could live on one.

The first workaround came from a lizard. Exendin-4, found in the venom of Heloderma lizards, the genus of the Gila monster, matches GLP-1 at about half its positions, works on the same receptor and is not cut by DPP-4. Made as the drug exenatide, it was approved for type 2 diabetes in 2005 and injected twice a day.

The fix: ride on albumin

Knudsen's team at Novo Nordisk kept human GLP-1 as the starting point and borrowed a trick from the body's own transport. Albumin is one of the most plentiful proteins in blood. It lasts for weeks, and part of its job is to carry fatty acids, which do not dissolve well on their own. Fix a fatty acid to a peptide and the peptide spends most of its time loosely held by albumin, too big for the kidneys to filter and partly shielded from the enzyme.

There is a catch, and the design turned on it. A molecule held by albumin is not touching the receptor. Only the free fraction works, so the tighter the grip, the less drug is active at any moment. A tail too short barely grips; a tail too long holds on too tightly and the drug loses potency. The team scanned the sequence position by position, found that a tail near the front end sharply cut the drug's strength, and put the tail on building block 26, near the back. They swapped the only other lysine, at 34, for arginine, so the tail could attach in one place only. The result, liraglutide, carries a 16-carbon fatty acid, has a half-life of about 13 hours, and is injected once a day. It was approved for diabetes in the US in 2010, and at a higher dose for obesity later.

Semaglutide pushed the same idea to a week. One building block at the front, position 8, was changed to an amino acid called Aib that DPP-4 cannot cut but the receptor still accepts. The tail became an 18-carbon fatty acid with an acid group at both ends, on a longer, water-friendly linker. The team tested tails from 12 to 22 carbons; 18 gave the best balance of albumin grip and receptor strength. In people it has a half-life of about a week, and the drug label puts its match with human GLP-1 at 94 percent.

Interactive Pick a molecule and how often it is taken, and watch the level in the blood over eight weeks. Slide the last-dose control to stop the drug and watch it wash out. Every control is a button or slider, so Tab and the arrow keys work too.

the molecule, and its half-life in the blood
one dose every
never stopped
peak ÷ trough, once steady
share of each gap at or above half the peak, once steady
doses to reach 90% of the steady level
after the last dose, time to fall to 3%

Drawn as if each dose reached the blood all at once, with one dose's peak set to 1. Under the skin it arrives more slowly (liraglutide peaks 8 to 12 hours after a shot, semaglutide 1 to 3 days), which rounds off the peaks but does not change the half-life. Half-lives: natural GLP-1 under the skin, Knudsen & Lau; liraglutide and semaglutide, their US prescribing information (about 1 week is drawn as 168 hours).

Why it cuts appetite

GLP-1 receptors sit in the pancreas, the gut and the brain, among other places. In animals, a glowing version of liraglutide reached a few spots where the brain's blood barrier is leaky and some appetite areas of the hypothalamus, and switched on nerve cells there. Removing GLP-1 receptors from brain nerve cells almost erased its effect on weight, while removing them from nerves outside the brain did not. In a 12-week study, people with obesity on semaglutide ate about 24 percent less across their meals, and burned no more energy than before. Exactly which circuits in the human brain carry the effect is still being worked out.

What the trials found

In the STEP 1 trial, reported in 2021, 1,961 adults with obesity, or overweight plus a related illness, and no diabetes took weekly semaglutide or placebo for 68 weeks alongside diet and exercise advice. The semaglutide group lost an average 14.9 percent of body weight; the placebo group lost 2.4. Tirzepatide, which acts on GLP-1's receptor and on the receptor of a second gut hormone, GIP, went further in its own trial: 20.9 percent at the top dose after 72 weeks, against 3.1 on placebo.

Weight was not the only measure. The SELECT trial followed 17,604 people who already had heart disease and overweight or obesity, but no diabetes, for a little over three years on average. A heart-related death, heart attack or stroke happened to 6.5 percent of those on semaglutide and 8.0 percent of those on placebo: a risk about a fifth lower.

Two costs come with it. Stomach trouble is common: in the trials behind the US label, 44 percent of people on the weekly injection reported nausea, against 16 percent on placebo. And the effect lasts only while the drug does. When a subset of STEP 1 participants stopped, they had regained about two-thirds of the weight they lost within a year.

Now: pills

A peptide is digested in the gut, so for years the weight-loss versions were injections. In December 2025 the US Food and Drug Administration approved a daily semaglutide tablet for weight loss. It carries an absorption helper, SNAC, that lets the drug cross the stomach wall, but only about 1 to 2 percent of each dose gets in. The tablet holds 25 mg, taken daily, against the weekly injection's 2.4. In April 2026 the FDA approved orforglipron, a daily pill from Eli Lilly that is not a peptide at all: a small molecule that switches on the same receptor and can be taken without the fasting rules the semaglutide tablet needs.

In one breath

GLP-1 is a gut hormone that says "fed" to the pancreas and the brain, and the body destroys it in minutes. The drugs keep the message and fix the lifetime: a fatty tail that lets albumin carry the hormone around for a day or a week, out of reach of the kidneys and partly shielded from the enzyme, and in semaglutide one changed building block so the enzyme cannot cut it. A week-long signal that you have eaten turns out to mean eating less.

Where this comes from

  1. The Discovery and Development of Liraglutide and Semaglutide linked only, not reproduced
    Lotte Bjerre Knudsen & Jesper Lau, Frontiers in Endocrinology 10:155 · 2019
    pmc.ncbi.nlm.nih.gov/articles/PMC6474072/
  2. Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1 linked only, not reproduced
    Hossein Ardehali, Journal of Clinical Investigation 134(19) · 2024
    www.jci.org/articles/view/186225
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity linked only, not reproduced
    Wilding, Batterham, Calanna et al. (STEP 1 Study Group), New England Journal of Medicine 384 · 2021
    pubmed.ncbi.nlm.nih.gov/33567185/
  4. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension linked only, not reproduced
    Wilding, Batterham, Davies et al., Diabetes, Obesity and Metabolism 24(8) · 2022
    pubmed.ncbi.nlm.nih.gov/35441470/
  5. Tirzepatide Once Weekly for the Treatment of Obesity linked only, not reproduced
    Jastreboff, Aronne, Ahmad et al. (SURMOUNT-1), New England Journal of Medicine 387 · 2022
    pubmed.ncbi.nlm.nih.gov/35658024/
  6. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes linked only, not reproduced
    Lincoff, Brown-Frandsen, Colhoun et al. (SELECT Trial Investigators), New England Journal of Medicine 389 · 2023
    pubmed.ncbi.nlm.nih.gov/37952131/
  7. WEGOVY (semaglutide) injection and tablets: US prescribing information, revised 06/2026 linked only, not reproduced
    Novo Nordisk; US Food and Drug Administration · 2026
    www.novo-pi.com/wegovy.pdf
  8. VICTOZA (liraglutide) injection: US prescribing information, revised 10/2025 linked only, not reproduced
    Novo Nordisk; US Food and Drug Administration · 2025
    www.novo-pi.com/victoza.pdf
  9. FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults linked only, not reproduced
    Novo Nordisk Inc. · 2025
    www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
  10. FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo, orforglipron) linked only, not reproduced
    US Food and Drug Administration, Office of the Commissioner · 2026
    www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
  11. FOUNDAYO (orforglipron) tablets: US prescribing information linked only, not reproduced
    US Food and Drug Administration · 2026
    www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
  12. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions linked only, not reproduced
    Eli Lilly and Company · 2026
    www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html